Emendo Biotherapeutics

Emendo Biotherapeutics company information, Employees & Contact Information

Emendo Biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy. We leverage our expertise in protein engineering to bring innovative and disruptive protein tools to resolve the bottleneck of the field.

Company Details

Employees
42
Founded
-
Address
400w E 61st St, New York,new York 10065,united States
Email
In****@****bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
New York, New York
Looking for a particular Emendo Biotherapeutics employee's phone or email?

Emendo Biotherapeutics Questions

News

EmendoBio Gene Editing Company Acquired by AnGes, Inc. - Business Wire

EmendoBio Gene Editing Company Acquired by AnGes, Inc. Business Wire

Anocca signs licensing deal for EmendoBio’s gene-editing tech - Pharmaceutical Technology

Anocca signs licensing deal for EmendoBio’s gene-editing tech Pharmaceutical Technology

AnGes laying off 110 EmendoBio employees three years after $250 million acquisition - CTech

AnGes laying off 110 EmendoBio employees three years after $250 million acquisition CTech

Emendo Biotherapeutics Achieves Milestone of Collaboration with Takeda for its OMNI Nuclease Program - GlobeNewswire

Emendo Biotherapeutics Achieves Milestone of Collaboration with Takeda for its OMNI Nuclease Program GlobeNewswire

Anocca & EmendoBio Team Up for Next-Gen Cell Therapy - Contract Pharma

Anocca & EmendoBio Team Up for Next-Gen Cell Therapy Contract Pharma

AnGes acquires EmendoBio for $250M - The Science Advisory Board

AnGes acquires EmendoBio for $250M The Science Advisory Board

Base Editors and Prime Editors Begin to Realize Their Clinical Promise - Genetic Engineering and Biotechnology News

Base Editors and Prime Editors Begin to Realize Their Clinical Promise Genetic Engineering and Biotechnology News

Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics - Business Wire

Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics Business Wire

Top Emendo Biotherapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant